Can stronger MS drugs halt silent brain damage? new study aims to find out
NCT ID NCT05962177
Summary
This study aims to understand if newer, high-efficacy MS treatments are better at slowing brain shrinkage (atrophy) than older, medium-efficacy treatments. Researchers will follow 400 people with relapsing-remitting MS for three years, using brain scans and other tests to track their disease. The goal is to gather better long-term evidence to help doctors choose the most effective treatments.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE SCLEROSIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Neurology Department, Hopital Gui de Chauliac
RECRUITINGMontpellier, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.